Skip to main content

Table 3 Meta-model inputs, regression coefficients, and performance metrics

From: Evidence-based cardiovascular magnetic resonance cost-effectiveness calculator for the detection of significant coronary artery disease

Variable

Meta-model coefficient

No imaging QALY

No imaging cost

Incremental QALY CMR, SPECT, CCTAa

Incremental cost CMR, SPECTa

Incremental cost CCTAb

Incremental QALY immediate ICAa

Incremental cost immediate ICAa

Intercept

32.5468

− 1124.0687

− 0.0108

− 930.0

− 1257.9

0.0246

− 832.2

Age in years

− 0.2343

− 239.1547

− 0.0002

12.8481

13.0193

− 0.0001

14.6191

Probability of patient having CAD

− 4.0808

50,086.6

0.1366

4335.6

3826.9

n/a

1643.7

Sensitivity of CMR

n/a

n/a

0.0484

1749.6

n/a

n/a

n/a

Specificity of CMR

n/a

n/a

0.0055

− 2649.1

n/a

n/a

n/a

Sensitivity of CCTA

n/a

n/a

n/a

n/a

1797.7

n/a

n/a

Specificity of CCTA

n/a

n/a

n/a

n/a

− 2655.3

n/a

n/a

Probability patient with false negative result returns to get coronary angiography within 1 year

0.0958

4034.8

− 0.0963

− 3562.4

− 3595.5

− 0.1082

− 4014.4

Annual rate of having a new MACE event for patients without CAD

− 75.8

287,992.6

n/a

n/a

n/a

0.0768

n/a

Post-1st year rate of having a MACE event for patients with CAD who received revascularization procedure

− 13.8625

29,804.1

0.2165

16,366.8

16,579.2

0.2434

18,378.7

Hazard rate ratio for patients who received medical therapy and revascularization procedure (natural log)

0.2203

528.3

− 0.1499

− 577.3

− 587.7

− 0.1685

− 645.2

Probability of dying during PCI

n/a

n/a

− 0.2742

n/a

n/a

− 0.3074

n/a

Probability of dying during CABG

n/a

n/a

− 0.1148

n/a

n/a

− 0.1263

n/a

Cost of CMR (or SPECT)

n/a

n/a

n/a

0.9987

n/a

n/a

n/a

Cost of CCTA

n/a

n/a

n/a

n/a

1.000

n/a

n/a

Cost of FFR-CT (added to CCTA for some patients)

n/a

n/a

n/a

n/a

0.4068

n/a

n/a

Cost of immediate coronary angiography with FFR

n/a

n/a

n/a

0.0534

0.0982

n/a

0.2967

Cost of immediate coronary angiography without FFR

n/a

n/a

n/a

0.0775

0.1416

n/a

0.4279

Cost of CABG

n/a

0.0851

n/a

0.0131

0.0133

n/a

0.0147

Cost of PCI

n/a

0.1901

n/a

0.0294

0.0300

n/a

0.0331

Acute (1st-year) cost of non-fatal MACE

n/a

0.1817

n/a

− 0.0034

− 0.0038

n/a

− 0.0045

Acute (1st-year) cost of fatal MACE

n/a

0.1233

n/a

− 0.0024

− 0.0021

n/a

− 0.0032

Utility of coronary heart disease health state

1.0242

n/a

− 0.0277

n/a

n/a

− 0.0312

n/a

Annual discount rate for costs and QALYs

− 126.8

− 82,131.3

− 0.0108

5653.8

5623.4

− 0.4461

6349.3

Meta model performance

No imaging QALY

No imaging Cost

Incremental QALY CMRb

Incremental cost CMRc

Incremental cost CCTAa

Incremental QALY immediate ICAa

Incremental cost immediate ICAa

External validation r-squared

0.9757

0.9133

0.9757

0.9982

0.9861

0.9999

0.9858

External validation deviation compared to Markov model

0.046%

− 0.025%

− 0.048% to 0.064%

− 0.031% to − 0.018%

0.007%

− 0.001%

− 0.040%

  1. n/a = not included (not beta coefficient not significant at an alpha = 0.05 level)
  2. aIncremental compared to ‘No Imaging’
  3. bIncremental compared to ‘No Imaging’; the same coefficients were used for incremental CMR, CTTA, and SPECT QALYs, given the exact same model structure and type of model inputs
  4. cIncremental compared to ‘No Imaging’; this meta-model (costs for CCTA) had different model inputs due to some patients receiving FFR (not the case for CMR or SPECT costs)
Back to article page

Journal of Cardiovascular Magnetic Resonance

ISSN: 1532-429X

Contact us